The Haystack Project
  • Home
  • About Us Participants Partners Board and Advisors
  • Priorities
  • PROTECT Rare
  • Rare Disease Approvals HEART Act
  • Speaker Series Payer Engagement Health Equity Rare Cancer
  • Inflation Reduction Act Medicare Section 340b Medicaid FDA ICER
  • Patient Stories
  • Join
  • Take Action
The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
Blue-Banner.png
The Haystack Project

Resources

The Haystack Project
  • Home/
  • About/
    • About Us
    • Participants
    • Partners
    • Board and Advisors
  • Priorities/
  • PROTECT Rare/
  • FDA/
    • Rare Disease Approvals
    • HEART Act
  • Programs/
    • Speaker Series
    • Payer Engagement
    • Health Equity
    • Rare Cancer
  • Policy/Comments/
    • Inflation Reduction Act
    • Medicare
    • Section 340b
    • Medicaid
    • FDA
    • ICER
  • Patient Stories/
  • Join/
  • Take Action/
May 09, 2025

Newborn Screening Coalition Letter→

May 09, 2025/ Tiara Logan

Read here.

May 09, 2025/ Tiara Logan/ /Source
Letters
FDA

Tiara Logan

April 22, 2025

US FDA’s Makary Floats Vague ‘Plausible Mechanism’ Approval Pathway For Rare Diseases→

April 22, 2025/ Tiara Logan

Read here.

April 22, 2025/ Tiara Logan/ /Source
News
FDA

Tiara Logan

April 22, 2025

Makary Pitches Rare Disease Approvals Based On ‘Plausible Mechanism’→

April 22, 2025/ Tiara Logan

Read here.

April 22, 2025/ Tiara Logan/ /Source
News
FDA

Tiara Logan

November 13, 2024

Pink Sheet: Woodcock Warns of ‘Excessive Worship Of The RCT,’ Pushes New Drug Approval Pathway→

November 13, 2024/ Tiara Logan

Read here.

November 13, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

October 29, 2024

Pink Sheet: Woodcock Throws Weight Behind Push For New Legislative ‘Substantial Evidence’ Standard For Rare Disease Drugs→

October 29, 2024/ Tiara Logan

Read here.

October 29, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

October 28, 2024

Inside Health Policy: Haystack Project Working With Lawmakers On Rare Disease Approval Legislation→

October 28, 2024/ Tiara Logan

Read here.

October 28, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

October 25, 2024

BioCentury: Perspective: A path forward for rare disease policy→

October 25, 2024/ Tiara Logan

Read here.

October 25, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

October 23, 2024

Inside Health Policy: Woodcock: RCT Standards Not Fit For Rare Disease Treatment Approval→

October 23, 2024/ Tiara Logan

Read here.

October 23, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

October 07, 2024

Pink Sheet: Clinical Trial Diversity Action Plans Need Timely US FDA Feedback, Groups Say→

October 07, 2024/ Tiara Logan

Read here.

October 07, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

September 26, 2024

Haystack FDA DAP Guidance Comment 9.26.24→

September 26, 2024/ Tiara Logan

Read here.

September 26, 2024/ Tiara Logan/ /Source
Comment Letters, Letters
FDA

Tiara Logan

June 15, 2024

FDA gets pointed input on ‘optimizing’ advisory committee panels→

June 15, 2024/ Tiara Logan

Read here.

June 15, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

April 17, 2024

Pink Sheet: Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length→

April 17, 2024/ Tiara Logan

Read here.

April 17, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

February 05, 2024

Pink Sheet: FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews→

February 05, 2024/ Tiara Logan

Read here.

February 05, 2024/ Tiara Logan/ /Source
News
FDA

Tiara Logan

November 15, 2023

NASEM meeting kicks off study on FDA and EMA processes for rare disease drugs→

November 15, 2023/ Tiara Logan

Read more.

November 15, 2023/ Tiara Logan/ /Source
FDA

Tiara Logan

November 10, 2023

Politico AgencyIQ Article: NASEM meeting kicks off study on FDA and EMA processes for rare disease drugs→

November 10, 2023/ Tiara Logan

Link to the article with press coverage of the meeting. See page 3 for what the reporter had to say about Haystack’s participation.

November 10, 2023/ Tiara Logan/ /Source
news, FDA

Tiara Logan

May 05, 2023

Haystack's letter to NASEM Requesting a meeting regarding the HEART Act→

May 05, 2023/ Michelle Osburn

Read more.

May 05, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
HEART Act, GAO, NAM, FDA

Michelle Osburn

May 04, 2023

Haystack requests meeting with GAO leadership and staff→

May 04, 2023/ Michelle Osburn

Read more.

May 04, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
HEART Act, GAO, NAM, FDA

Michelle Osburn

March 09, 2023

Haystack's Project Letter to FDA on the Implementation of the HEART Act→

March 09, 2023/ Michelle Osburn

Read more.

March 09, 2023/ Michelle Osburn/ /Source
Comment Letters, Letters
HEART Act, GAO, NAM, FDA

Michelle Osburn

August 10, 2021

Tuberous Sclerosis Alliance opposes MACPAC recommendations regarding differential Medicaid rebates for FDA accelerated approval drugs→

August 10, 2021/ Rebecca Balliet

Read more.

August 10, 2021/ Rebecca Balliet/ /Source
Comment Letters, Letters
medicaid, Medicaid, FDA

Rebecca Balliet

About Us

The Issues

Resources

News & Updates

© 2020 Haystack Project. All Rights Reserved. 

 

Contact Us

Please consider making a tax-deductible donation to support the Haystack Project today.

The Haystack Project is a 501(c)3 nonprofit that brings together patients organizations representing patients suffering from or caring for patients with extremely rare diseases. Our mission is to educate policymakers and other stakeholders about the need for policies that recognize the unique circumstances of extremely rare conditions and treatments and expand incentives critical to ensuring they can reach patients.